A carregar...
Publicação
Synergy valuation in the Pfizer - Seagen acquisition - influencing factors on abnormal returns in R & D intensive industries for non - Us acquirers
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 2.15 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
This thesis examines the Pfizer-Seagen acquisition, a pivotal deal in the pharmaceutical
industry. It starts with a literature review on valuation methods and further analyses the strategic
motivations and financial implications of mergers and acquisitions in the industry. The thesis
assesses both companies' market positions, strategies, and financial health, to perform two
comprehensive standalone valuations. It also conducts a combined valuation to explore
potential synergies and economically feasible offer prices, comparing these to Pfizer's
announced offer. Additionally, the thesis analyses stock reactions post M&A announcements
for non-U.S. acquirers in R&D intensive industries.
Descrição
Palavras-chave
Mergers and acquisitions Valuation Pharmaceutical industry Pfizer Seagen